Risk factors for bronchiectasis in children with cystic fibrosis

Peter D Sly1, Catherine L Gangell, Linping Chen

  • 1Queensland Children's Medical Research Institute, Brisbane, Australia. p.sly@uq.edu.au

Insights

Early life neutrophil elastase activity in cystic fibrosis patients predicts bronchiectasis. This finding highlights key risk factors for early-onset lung disease in children with CF.

Area of Science:

  • Pediatric Pulmonology
  • Cystic Fibrosis Research
  • Respiratory Medicine

Background:

  • Bronchiectasis is a common and progressive complication in cystic fibrosis (CF) that develops early in infancy.
  • Identifying risk factors for early bronchiectasis is crucial for timely intervention in CF patients.

Purpose of the Study:

  • To determine risk factors associated with the onset and persistence of bronchiectasis in infants diagnosed with cystic fibrosis.
  • To analyze data from the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) program.

Main Methods:

  • Longitudinal analysis of data from 127 infants diagnosed with CF via newborn screening.
  • Chest computed tomography (CT) and bronchoalveolar lavage (BAL) were performed at 3 months, 1, 2, and 3 years of age.
  • Multivariate analyses were used to identify risk factors for bronchiectasis detection.

Main Results:

  • The prevalence of bronchiectasis increased from 29.3% at 3 months to 61.5% by 3 years of age.
  • Key risk factors identified include meconium ileus, respiratory symptoms, free neutrophil elastase activity in BAL fluid, and gas trapping on expiratory CT.
  • Elevated neutrophil elastase activity at 3 months was significantly associated with persistent bronchiectasis at later ages.

Conclusions:

  • Neutrophil elastase activity in bronchoalveolar lavage fluid during early infancy is a significant predictor of early-onset bronchiectasis in children with cystic fibrosis.
  • These findings underscore the importance of monitoring neutrophil elastase activity for early detection and management of lung disease in CF.
Abstract

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...